Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias

Human Mutation

Volumn 33, Issue 1, 2012, Pages 29-41

  Foldynova Trantirkova, Silvie ^a   Wilcox, William R ^b,c   Krejci, Pavel ^b,c,d,e  

^a INSTITUTE OF PARASITOLOGY   (Czech Republic)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASARYK UNIVERSITY   (Czech Republic)

^e INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Chondrocyte; FGF; FGFR3; MAP kinase; Skeletal dysplasia

Indexed keywords

ARGININE; CYSTEINE; DISULFIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC PEPTIDE TYPE C; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; STAT1 PROTEIN;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; AMINO ACID SUBSTITUTION; BLADDER CARCINOMA; BONE DYSPLASIA; BONE GROWTH; BONE MATRIX; CARTILAGE; CARTILAGE CELL; CELL PROLIFERATION; DIMERIZATION; DISULFIDE BOND; ENCHONDRAL OSSIFICATION; EXTRACELLULAR MATRIX; GENE MUTATION; GROWTH INHIBITION; GROWTH REGULATION; HETEROZYGOTE; HUMAN; HYDROGEN BOND; LIGAND BINDING; MITOGENESIS; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NEVUS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEBORRHEIC KERATOSIS; SEMINOMA; SIGNAL TRANSDUCTION; THANATOPHORIC DWARFISM; UTERINE CERVIX CARCINOMA;

BONE AND BONES; CARTILAGE; CELL COMMUNICATION; CELL PROLIFERATION; CHONDROCYTES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GENES, LETHAL; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; NATRIURETIC PEPTIDE, C-TYPE; OSTEOCHONDRODYSPLASIAS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR;

EID: 84857688284     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21636     Document Type: Review

References (157)

1. Aikawa T, Segre GV, Lee K. 2001. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem 276:29347-29352.
2. Aviezer D, Golembo M, Yayon A. 2003. Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia-genetic short limbed dwarfism.Curr Drug Targets 4:353-365.
3. Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. 1991. Flg-2, a new member of the family of fibroblast growth factor receptors. Oncogene 6:1089-1092.
4. Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI and others. 2004. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75:27-34.
5. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. 2000. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84-89.
6. Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M. 2008. Achondroplasia. Best Pract Res Clin Rheumatol 22:3-18.
7. Beever JE, Smit MA, Meyers SN, Hadfield TS, Bottema C, Albretsen J, Cockett NE. 2006. A single-base change in the tyrosine kinase II domain of ovine FGFR3 causes hereditary chondrodysplasia in sheep. Anim Genet 37:66-71.
8. Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, HortonWA,Machado M, Kaitila I, McIntosh I, Francomano CA. 1995. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 56:368-373.
9. BellusGA,Spector EB, SpeiserPW,Weaver CA,GarberAT,BrykeCR, Israel J, Rosengren SS, Webster MK, Donoghue DJ and others. 2000. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67:1411-1421.
10. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. 2006. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 119:380-387.
11. Bonaventure J,Horne WC, Baron R. 2007. The localization of FGFR3mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor. FEBS J 274:3078-3093.
12. Brazil DP, Hemmings BA. 2001. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26:657-664.
13. Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR. 1999. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am J Med Genet 84:476-480.
14. Brodie SG, Kitoh H, Lipson M, Sifry-Platt M, Wilcox WR. 1998. Thanatophoric dysplasia type I with syndactyly. Am J Med Genet 80:260-262.
15. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. 1999. Frequent activatingmutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20.
16. Chau M, Forcinito P, Andrade AC, Hegde A, Ahn S, Lui JC, Baron J, Nilsson O. 2011. Organization of the Indian hedgehog-parathyroid hormone-related protein system in the postnatal growth plate. J Mol Endocrinol 47:99-107.
17. Chen J, Lee BH,Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A and others. 2005. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24:8259-8267.
18. Chen L, Adar R, Yang X, Monsonego EO, Li C, Hauschka PV, Yayon A, Deng CX. 1999. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest 104:1517-1525.
19. Chen L, Li C, Qiao W, Xu X, Deng C. 2001. A Ser(365)->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 10:457-465.
20. Chen X, Macica C, Nasiri A, Broadus AE. 2008. Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormonerelated protein. Arthritis Rheum 58:3788-3797.
21. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL. 2001. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97:729-736.
22. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264.
23. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. 1996. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 272:719-722.
24. Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA. 2004. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101:609-614.
25. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y and others. 2001. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 98:4016-4021.
26. Colvin JS, Bohne BA, Harding GW,McEwen DG, Ornitz DM. 1996. Skeletal overgrowth and deafness inmice lacking fibroblast growth factor receptor 3.Nat Genet 12:390-397.
27. Cormier S, Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Bonaventure J, Silve C. 2002. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations. Am J Pathol 161:1325-1335.
28. d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. 1998. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 9:71-78.
29. Dagoneau N, Scheffer D, Huber C, Al-Gazali LI, Di Rocco M, Godard A, Martinovic J, Raas-Rothschild A, Sigaudy S, Unger S and others. 2004. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet 74:298-305.
30. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. 2005. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16:233-247.
31. Dailey L, Laplantine E, Priore R, Basilico C. 2003. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol 161:1053-1066.
32. Daughaday WH, Rotwein P. 1989. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68-91.
33. Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF. 2002. rAAVmediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 62:3077-3083.
34. de Frutos CA, Vega S, Manzanares M, Flores JM, Huertas H, Martinez-Frias ML, Nieto MA. 2007. Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Dev Cell 13:872-883.
35. Delezoide AL, Lasselin-Benoist C, Legeai-Mallet L, Brice P, Senee V, Yayon A,Munnich A, Vekemans M, Bonaventure J. 1997. Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. Hum Mol Genet 6:1899-1906.
36. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921.
37. Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450.
38. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. 1995. Toward a molecular understanding of skeletal development. Cell 80:371-378.
39. Franke TF, Kaplan DR, Cantley LC, Toker A. 1997. Direct regulation of the Akt protooncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275:665-668.
40. Garbers DL. 1990. Guanylate cyclase receptor family. Recent Prog Horm Res 46:85-96; discussion 96-97.
41. Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, McVean GA, Meyts ER, Wilkie AO. 2009. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 41:1247-1252.
42. GuoC,DegninCR, LaederichMB, LunstrumGP,HoldenP,Bihlmaier J,KrakowD,Cho YJ, Horton WA. 2008. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: A severe form of human achondroplasia. Cell Signal 20:1471-1477.
43. Hadari YR,Kouhara H, Lax I, Schlessinger J. 1998.Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 18:3966-3973.
44. Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A. 2006. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 116:2201-2207.
45. Hall BD, Spranger J. 1979. Hypochondroplasia: Clinical and radiological aspects in 39 cases. Radiology 133:95-100.
46. Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T, Seino Y, Tanaka H. 2007. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. Bone 41:273-281.
47. Harada D, Yamanaka Y, Ueda K, Tanaka H, Seino Y. 2009. FGFR3-related dwarfism and cell signaling. J Bone Miner Metab 27:9-15.
48. Hart KC, Robertson SC, Donoghue DJ. 2001. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 12:931-942.
49. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. 2000. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19:3309-3320.
50. Henderson JE, Naski MC, Aarts MM, Wang D, Cheng L,Goltzman D, Ornitz DM. 2000. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. J Bone Miner Res 15:155-165.
51. HortonWA, Hall JG, Hecht JT. 2007. Achondroplasia. Lancet 370:162-172.
52. Ibrahimi OA, Yeh BK, Eliseenkova AV, Zhang F, Olsen SK, Igarashi M, Aaronson SA, Linhardt RJ, Mohammadi M. 2005. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol 25:671-684.
53. IwataT,Chen L, LiC,OvchinnikovDA,Behringer RR, FrancomanoCA,DengCX. 2000. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet 9:1603-1613.
54. Iwata T, Li CL, Deng CX, Francomano CA. 2001. Highly activated Fgfr3 with the K644Mmutation causes prolonged survival in severe dwarf mice.HumMol Genet 10:1255-1264.
55. Johnson DE,Williams LT. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41.
56. Karaplis AC, Luz A, Glowacki J, Bronson RT,Tybulewicz VL, Kronenberg HM, Mulligan RC. 1994. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-289.
57. Karsenty G, Ducy P, Starbuck M, Priemel M, Shen J, Geoffroy V, Amling M. 1999. Cbfa1 as a regulator of osteoblast differentiation and function. Bone 25:107-108.
58. Kitoh H, Brodie SG, Kupke KG, Lachman RS, Wilcox WR. 1998. Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online. Hum Mutat 12:362-363.
59. Klint P, Claesson-Welsh L. 1999. Signal transduction by fibroblast growth factor receptors. Front Biosci 4:D165-D177.
60. Koike M, Yamanaka Y, Inoue M, Tanaka H, Nishimura R, Seino Y. 2003. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK. J Bone Miner Res 18:2043-2051.
61. Kolupaeva V, Laplantine E, Basilico C. 2008. PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF. PLoS One 3:e3447.
62. Kosher RA, Kulyk WM, Gay SW. 1986. Collagen gene expression during limb cartilage differentiation. J Cell Biol 102:1151-1156.
63. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. 1997. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89:693-702.
64. Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, Mekikian P, Wilcox WR. 2004. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res 297:152-164.
65. Krejci P, Krakow D, Mekikian PB, Wilcox WR. 2007a. Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage. Pediatr Res 61:267-272.
66. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, Wilcox WR. 2005. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118:5089-5100.
67. Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson LM, Wilcox WR. 2007b. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of ERK MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem 282:2929-2936.
68. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, Aklian A, Smutny J, Bryja V, Kozubik A and others. 2010a. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem 285:20644-20653.
69. Krejci P, Pejchalova K, Wilcox WR. 2007c. Simple, mammalian cell-based assay for identification of inhibitors of the ERK MAP kinase pathway. Invest New Drugs 25:391-395.
70. Krejci P, Prochazkova J, Bryja V, Jelinkova P, Pejchalova K, Kozubik A, Thompson LM, Wilcox WR. 2009. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal 21:151-160.
71. Krejci P, Prochazkova J, Smutny J, Chlebova K, Lin P, Aklian A, Bryja V, Kozubik A, Wilcox WR. 2010b. FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone 47:102-110.
72. Krejci P, Salazar L, Goodridge HS, Kashiwada TA, Schibler MJ, Jelinkova P, Thompson LM, Wilcox WR. 2008a. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J Cell Sci 121:272-281.
73. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR. 2008b. Analysis of STAT1 activation by six FGFR3mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One 3:e3961.
74. Kronenberg HM. 2006. PTHrP and skeletal development. AnnNY Acad Sci 1068:1-13.
75. L'Hote CG, Knowles MA. 2005. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304:417-431.
76. Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA. 2011. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: Implications for therapeutic manipulation. J Biol Chem:[Epub ahead of print] 286:19597-19604.
77. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LH, Ho C, Mulligan RC and others. 1996. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666.
78. Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J. 2002. The docking protein FRS2alpha controls aMAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell 10:709-719.
79. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. 1998. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273:13007-13014.
80. Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J. 2004. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 34:26-36.
81. Li C, Chen L, Iwata T, KitagawaM, Fu XY, Deng CX. 1999. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism inmice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 8:35-44.
82. Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Hawley RG, Stewart AK. 2001. Themyeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 97:2413-2419.
83. Lievens PM, Liboi E. 2003. The thanatophoric dysplasia type IImutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278:17344-17349.
84. Lievens PM, Mutinelli C, Baynes D, Liboi E. 2004. The kinase activity of fibroblast growth factor receptor 3with activation loopmutations affects receptor trafficking and signaling. J Biol Chem 279:43254-43260.
85. Lievens PM, Roncador A, Liboi E. 2006. K644E/MFGFR3mutants activate ERK1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. J Mol Biol 357:783-792.
86. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.
87. Liu Z, Xu J, Colvin JS, Ornitz DM. 2002. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 16:859-869.
88. Long F, Zhang XM, Karp S, Yang Y, McMahon AP. 2001. Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development 128:5099-5108.
89. Logie A, Dunois-Larde C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X and others. 2005. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 14:1153-1160.
90. Macsai CE, Foster BK, Xian CJ. 2008. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol 215:578-587.
91. Maroteaux P, Lamy M, Robert JM. 1967. [Thanatophoric dwarfism]. Presse Med 75:2519-2524.
92. Martinez-Frias ML, de Frutos CA, Bermejo E, Nieto MA. 2010. Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia. Am J Med Genet A 152A:245-255.
93. Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bukulmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I and others. 2009. FGFR3 promotes synchondrosis closure and fusion of ossification centers through theMAPK pathway. Hum Mol Genet 18:227-240.
94. Meyer AN, McAndrew CW, Donoghue DJ. 2008. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 68:7362-7370.
95. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV,Green D, Schlessinger J,Hubbard SR. 1998.Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17:5896-5904.
96. MohammadiM,McMahonG, SunL,Tang C,HirthP,Yeh BK,Hubbard SR, Schlessinger J. 1997. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955-960.
97. Monsonego-Ornan E,AdarR, FefermanT, Segev O,YayonA. 2000. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20:516-522.
98. Monsonego-Ornan E, Adar R, Rom E, Yayon A. 2002. FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation. FEBS Lett 528:83-89.
99. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B. 2004. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18:290-305.
100. Nakao K, Ogawa Y, Suga S, Imura H. 1992.Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 10:907-912.
101. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y. 2010. Newmolecular and biologicalmechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 16:2792-2802.
102. Naski MC, Colvin JS, Coffin JD, Ornitz DM. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988.
103. Naski MC, Wang Q, Xu J, Ornitz DM. 1996.Graded activation of fibroblast growthfactor receptor 3 bymutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233-237.
104. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson LM. 2005. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet 14:1529-1538.
105. Oberklaid F, Danks DM, Jensen F, Stace L, Rosshandler S. 1979. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J Med Genet 16:140-146.
106. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. 2001. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA 98:6074-6079.
107. Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16:205-213.
108. Passos-Bueno MR,Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. 1999. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14:115-125.
109. Pejchalova K, Krejci P, Wilcox WR. 2007. C-natriuretic peptide: an important regulator of cartilage. Mol Genet Metab 92:210-215.
110. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG and others. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352-1365.
111. Peters K, Ornitz D, Werner S, Williams L. 1993. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol 155:423-430.
112. Pfeifer A, Aszodi A, Seidler U, Ruth P, Hofmann F, Fassler R. 1996. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 274:2082-2086.
113. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK. 2000. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95:992-998.
114. Pogue R, Lyons K. 2006. BMP signaling in the cartilage growth plate. Curr Top Dev Biol 76:1-48.
115. Prinos P, Costa T, Sommer A, Kilpatrick MW, Tsipouras P. 1995. A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet 4:2097-2101.
116. Priore R, Dailey L, Basilico C. 2006. Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J Cell Physiol 207:800-808.
117. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K and others. 2009. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 119:1216-1229.
118. Raffioni S, Zhu YZ, Bradshaw RA, Thompson LM. 1998. Effect of transmembrane and kinase domainmutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. Amodel for the control of receptor tyrosine kinase activation. J Biol Chem 273:35250-35259.
119. Raucci A, Laplantine E, Mansukhani A, Basilico C. 2004. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem 279:1747-1756.
120. Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A. 2001. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): Comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20:3553-3562.
121. Roovers K, Assoian RK. 2000. Integrating theMAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22:818-826.
122. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM,Maroteaux P, LeMerrer M, Munnich A. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254.
123. Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach J, Maroteaux P, Munnich A, Le Merrer M. 1996. Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 33:749-752.
124. Rousseau F, Saugier P, Le Merrer M, Munnich A, Delezoide AL, Maroteaux P, Bonaventure J, Narcy F, Sanak M. 1995. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat Genet 10:11-12.
125. Sahni M, Ambrosetti DC,Mansukhani A, Gertner R, Levy D, Basilico C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13:1361-1366.
126. Sahni M, Raz R, Coffin JD, Levy D, Basilico C. 2001. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128:2119-2129.
127. Sanjay A, Horne WC, Baron R. 2001. The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases. Sci STKE 2001:pe40.
128. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, Kowolik C, Xin H, Chen L,Wang Y and others. 2011. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25:538-550.
129. Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth GE, Murakami S. 2011. Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal. J Orthop Res 29:375-379.
130. Segev O, Chumakov I, Nevo Z, Givol D, Madar-Shapiro L, Sheinin Y, Weinreb M, Yayon A. 2000. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. Hum Mol Genet 9:249-258.
131. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342.
132. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M,Martin TJ. 2004. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113:379-389.
133. SuWC, KitagawaM, Xue N, Xie B,Garofalo S, Cho J, Deng C,HortonWA, Fu XY. 1997. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386:288-292.
134. Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB. 1998. Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol Cell Biol 18:6983-6994.
135. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR and others. 1999. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64:722-731.
136. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ. 1995. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321-328.
137. Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC, Bamshad MJ. 2006. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 79:935-941.
138. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D,Heise C, Stewart AK. 2005. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941-2948.
139. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, Chumakov I, Singer Y, Chang H, Liang SB and others. 2006. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107:4039-4046.
140. Tsuji T, Kunieda T. 2005. A loss-of-functionmutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem 280:14288-14292.
141. Ueda K, Yamanaka Y, Harada D, Yamagami E, Tanaka H, Seino Y. 2007. PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone 41:13-18.
142. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. 1996. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622.
143. Waller DK, Correa A, Vo TM,Wang Y, Hobbs C, Langlois PH, Pearson K, Romitti PA, Shaw GM, Hecht JT. 2008. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am J Med Genet A 146A:2385-2389.
144. Webster MK, D'Avis PY, Robertson SC, Donoghue DJ. 1996. Profound ligandindependent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16:4081-4087.
145. Webster MK, Donoghue DJ. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found inachondroplasia. EMBO J 15:520-527.
146. Weizmann S, Tong A, Reich A, Genina O, Yayon A, Monsonego-Ornan E. 2005. FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: Implications for endochondral ossification. Matrix Biol 24:520-529.
147. Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS,Wasmuth JJ, Thompson LM, Rimoin DL. 1998. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 78:274-281.
148. Wong A, Lamothe B, Lee A, Schlessinger J, Lax I. 2002. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 99:6684-6689.
149. Xin X, Abrams TJ,Hollenbach PW, Rendahl KG, Tang Y,Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK and others. 2006. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12:4908-4915.
150. Yamamoto A, Nagano T, Takehara S, Hibi M, Aizawa S. 2005. Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF. Cell 120:223-235.
151. Yamanaka Y, Tanaka H, Koike M, Nishimura R, Seino Y. 2003. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J Bone Miner Res 18:1395-1403.
152. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M and others. 2004. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80-86.
153. Yu CF, Liu ZX,Cantley LG. 2002. ERK negatively regulates the epidermal growth factormediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem 277:19382-19388.
154. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. 2004. VEGFA is necessary for chondrocyte survival during bone development. Development 131:2161-2171.
155. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. 2006. Receptor specificity of the fibroblast growth factor family. The completemammalian FGF family. J Biol Chem 281:15694-15700.
156. Zhang Y, Qu Z, Kim S, Shi V, Liao B, Kraft P, Bandaru R, Wu Y, Greenberger LM, Horak ID. 2011. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18:326-333.
157. Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Slovak ML, Liu X, Luo J, Yen Y. 2005. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 4:787-798.